U.S. FOOD & DRUG ADMINISTRATION
CENTER FOR FOOD SAFETY & APPLIED NUTRITION

February 15, 2018

Frank Jaksch
Founder and CEO
ChromaDex, Inc.
10005 Muirlands Blvd., Suite G
Irvine, CA 92618

Re: Docket Number FDA-2017-P-5082

Dear Mr. Jaksch:

This responds to your citizen petition dated August 18, 2017, under docket number FDA-2017-P-5082 requesting that the Food and Drug Administration (FDA or we) investigate and take appropriate remedial action against Elysium Health, Inc. ("Elysium"), which has made, offers for sale and sells, as a dietary supplement, a product named "Basis". This also responds to the supplement dated January 16, 2018, under the same docket number.

We are advising you, in accordance with 21 CFR 10.30(e)(2), that we have not reached decision on your petition within the first 180 days due to competing agency priorities. However, be advised that your petition is currently under active evaluation by our staff.

Sincerely,

Steven J. Tave
Director
Office of Dietary Supplement Programs
Center for Food Safety
and Applied Nutrition

CC: Dockets Management Branch, HFA-305

U.S. Food & Drug Administration
Center for Food Safety & Applied Nutrition
5001 Campus Drive
College Park, MD 20740